Stay updated on Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial
Sign up to get notified when there's something new on the Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial page.

Latest updates to the Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe Publications section adds a note that publications are provided voluntarily by the person entering information about the study and pertain to the study results, and the revision label is updated to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe page footer notice regarding government funding/operating status was removed, with no impact on the study details, eligibility criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedThe record now includes published results for NCT02225587, citing a 2021 Hum Vaccin Immunother article and associated GMT data. This addition updates the study results section with analyzed outcomes.SummaryDifference0.4%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference3%

- Check78 days agoChange DetectedRemoved multiple drug-safety topics and added a new version tag (v3.1.0), indicating a content cleanup and revision upgrade.SummaryDifference0.4%

- Check93 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2 and the Back to Top element was removed; no core content or critical data changed.SummaryDifference0.2%

Stay in the know with updates to Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Prevnar 13/Pneumovax 23 Safety/Immunogenicity in Adults 50+ Clinical Trial page.